A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 Versus Treatment Choice (TC) in Adults With Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy

Trial Profile

A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 Versus Treatment Choice (TC) in Adults With Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Mar 2018

At a glance

  • Drugs Guadecitabine (Primary) ; Azacitidine; Cytarabine; Decitabine
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms ASTRAL-1
  • Sponsors Astex Pharmaceuticals; Otsuka Pharmaceutical
  • Most Recent Events

    • 22 Dec 2017 Planned End Date changed from 1 Apr 2018 to 1 Jun 2018.
    • 22 Dec 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Jun 2018.
    • 21 Dec 2017 Planned End Date changed from 1 Dec 2017 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top